
robert Wynn

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5289833/publications.pdf Version: 2024-02-01



DOREDT W/VNN

#	Article	IF	CITATIONS
1	International retrospective study of allogeneic hematopoietic cell transplantation for activated PI3K-delta syndrome. Journal of Allergy and Clinical Immunology, 2022, 149, 410-421.e7.	1.5	34
2	B-cell depletion abrogates immune mediated cytopenia and rejection of cord blood transplantation in Hurler syndrome. Bone Marrow Transplantation, 2022, 57, 38-42.	1.3	5
3	<i>DNMT3A</i> overgrowth syndrome is associated with the development of hematopoietic malignancies in children and young adults. Blood, 2022, 139, 461-464.	0.6	9
4	Hematopoietic stem cell transplantation for adolescents and adults with inborn errors of immunity: an EBMT IEWP study. Blood, 2022, 140, 1635-1649.	0.6	20
5	Current and Future Treatment of Mucopolysaccharidosis (MPS) Type II: Is Brain-Targeted Stem Cell Gene Therapy the Solution for This Devastating Disorder?. International Journal of Molecular Sciences, 2022, 23, 4854.	1.8	5
6	The evolution of pulmonary function in childhood onset Mucopolysaccharidosis type I. Molecular Genetics and Metabolism, 2021, 132, 94-99.	0.5	4
7	Outcome After Cord Blood Transplantation Using Busulfan Pharmacokinetics-Targeted Myeloablative Conditioning for Hurler Syndrome. Transplantation and Cellular Therapy, 2021, 27, 91.e1-91.e4.	0.6	6
8	Consensus opinion on immune-mediated cytopenias after hematopoietic cell transplant for inherited metabolic disorders. Bone Marrow Transplantation, 2021, 56, 1238-1247.	1.3	9
9	Excellent overall and chronic graftâ€ <i>versus</i> â€hostâ€diseaseâ€free eventâ€free survival in Fanconi anaemia patients undergoing matched related―and unrelatedâ€donor bone marrow transplantation using alemtuzumab–Flu–Cy: the UK experience. British Journal of Haematology, 2021, 193, 804-813.	1.2	10
10	A multicentre, multinational, prospective, observational registry study of defibrotide in patients diagnosed with veno-occlusive disease/sinusoidal obstruction syndrome after haematopoietic cell transplantation: an EBMT study. Bone Marrow Transplantation, 2021, 56, 2454-2463.	1.3	11
11	Clonal expansion of T memory stem cells determines early anti-leukemic responses and long-term CAR T cell persistence in patients. Nature Cancer, 2021, 2, 629-642.	5.7	59
12	Effectiveness of early hematopoietic stem cell transplantation in preventing neurocognitive decline in aspartylglucosaminuria: A case series. JIMD Reports, 2021, 61, 3-11.	0.7	2
13	COVIDâ€19 infection in paediatric recipients of allogeneic stem cell transplantation: the UK experience. British Journal of Haematology, 2021, 194, e74-e77.	1.2	12
14	Routine management, healthcare resource use and patient and carerâ€reported outcomes of patients with transfusionâ€dependent βâ€thalassaemia in the United Kingdom: A mixed methods observational study. EJHaem, 2021, 2, 738-749.	0.4	7
15	CAR T cells with dual targeting of CD19 and CD22 in pediatric and young adult patients with relapsed or refractory B cell acute lymphoblastic leukemia: a phase 1 trial. Nature Medicine, 2021, 27, 1797-1805.	15.2	125
16	Immune reconstitution following umbilical cord blood transplantation: IRES, a study of UK paediatric patients. EJHaem, 2020, 1, 208-218.	0.4	3
17	Cord blood CD8+ T-cell expansion following granulocyte transfusions eradicates refractory leukemia. Blood Advances, 2020, 4, 4165-4174.	2.5	11
18	HSCT provides effective treatment for lymphoproliferative disorders in children with primary immunodeficiency. Journal of Allergy and Clinical Immunology, 2020, 146, 447-450.	1.5	8

ROBERT WYNN

#	Article	IF	CITATIONS
19	A role for human leucocyte antigens in the susceptibility to SARSâ€Covâ€2 infection observed in transplant patients. International Journal of Immunogenetics, 2020, 47, 324-328.	0.8	35
20	Intention to Treat Analysis of Real-World Outcomes Following Tisgenlecleucel Therapy for Pediatric and Young Adult ALL through a National Access Programme. Blood, 2020, 136, 18-19.	0.6	2
21	Enhanced CAR T cell expansion and prolonged persistence in pediatric patients with ALL treated with a low-affinity CD19 CAR. Nature Medicine, 2019, 25, 1408-1414.	15.2	394
22	Recommendations for the management of MPS VI: systematic evidence- and consensus-based guidance. Orphanet Journal of Rare Diseases, 2019, 14, 118.	1.2	30
23	Recommendations for the management of MPS IVA: systematic evidence- and consensus-based guidance. Orphanet Journal of Rare Diseases, 2019, 14, 137.	1.2	62
24	Report of Resistant Varicella Zoster Infection Treated With Donor Lymphocyte Infusion in a Pediatric Oncology Patient. Pediatric Infectious Disease Journal, 2019, 38, 513-515.	1.1	1
25	Association between adenovirus viral load and mortality in pediatric allo-HCT recipients: the multinational AdVance study. Bone Marrow Transplantation, 2019, 54, 1632-1642.	1.3	25
26	Severe type I interferonopathy and unrestrained interferon signaling due to a homozygous germline mutation in <i>STAT2</i> . Science Immunology, 2019, 4, .	5.6	80
27	Therapy of Paediatric B-ALL with a Fast Off Rate CD19 CAR Leads to Enhanced Expansion and Prolonged CAR T Cell Persistence in Patients with Low Bone Marrow Tumour Burden, and Is Associated with a Favourable Toxicity Profile. Blood, 2019, 134, 225-225.	0.6	3
28	A Multi-Center, Multinational, Prospective Observational Registry Study of Defibrotide in Patients Diagnosed with Severe Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome (VOD/SOS) after Hematopoietic Cell Transplantation (HCT). Blood, 2019, 134, 1972-1972.	0.6	0
29	Routine Management, Healthcare Resource Use and Patient/Caregiver-Reported Outcomes of Patients with Transfusion-Dependent β-Thalassaemia in the United Kingdom: A Mixed Methods Observational Study. Blood, 2019, 134, 3550-3550.	0.6	0
30	Management of adenovirus infection in patients after haematopoietic stem cell transplantation: Stateâ€ofâ€ŧheâ€art and realâ€ŀife current approach. Reviews in Medical Virology, 2018, 28, e1980.	3.9	75
31	Refining the phenotype associated with biallelic <i>DNAJC21</i> mutations. Clinical Genetics, 2018, 94, 252-258.	1.0	33
32	High transplant-related mortality associated with haematopoietic stem cell transplantation for paediatric therapy-related acute myeloid leukaemia (t-AML). A study on behalf of the United Kingdom Paediatric Blood and Bone Marrow Transplant Group. Bone Marrow Transplantation, 2018, 53, 1165-1169.	1.3	6
33	The effect of haemopoietic stem cell transplantation on the ocular phenotype in mucopolysaccharidosis type I (Hurler). Acta Ophthalmologica, 2018, 96, 494-498.	0.6	5
34	Diagnosis and severity criteria for sinusoidal obstruction syndrome/veno-occlusive disease in pediatric patients: a new classification from the European society for blood and marrow transplantation, 2018, 53, 138-145.	1.3	225
35	Outcome of domino hematopoietic stem cell transplantation in human subjects: An international case series. Journal of Allergy and Clinical Immunology, 2018, 142, 1628-1631.e4.	1.5	1
36	Treatment dilemmas in asymptomatic children with primary hemophagocytic lymphohistiocytosis. Blood, 2018, 132, 2088-2096.	0.6	17

ROBERT WYNN

#	Article	IF	CITATIONS
37	Simultaneous Targeting of CD19 and CD22: Phase I Study of AUTO3, a Bicistronic Chimeric Antigen Receptor (CAR) T-Cell Therapy, in Pediatric Patients with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia (r/r B-ALL): Amelia Study. Blood, 2018, 132, 279-279.	0.6	28
38	Allogeneic stem cell transplantation for refractory acute myeloid leukemia in pediatric patients: the UK experience. Bone Marrow Transplantation, 2017, 52, 825-831.	1.3	20
39	Ascitic fluid drainage using a peritoneal dialysis catheter to prevent and treat multiâ€organ dysfunction in venoâ€occlusive disease in children undergoing hematopoietic stem cell transplantation. Pediatric Blood and Cancer, 2017, 64, e26469.	0.8	3
40	Brincidofovir is highly efficacious in controlling adenoviremia in pediatric recipients of hematopoietic cell transplant. Blood, 2017, 129, 2033-2037.	0.6	95
41	Long term survival and cardiopulmonary outcome in children with Hurler syndrome after haematopoietic stem cell transplantation. Journal of Inherited Metabolic Disease, 2017, 40, 455-460.	1.7	29
42	Haematopoietic Stem Cell Transplantation Arrests theÂProgression of Neurodegenerative Disease in Late-Onset Tay-Sachs Disease. JIMD Reports, 2017, 41, 17-23.	0.7	18
43	Allele-level HLA matching for umbilical cord blood transplantation for non-malignant diseases in children: a retrospective analysis. Lancet Haematology,the, 2017, 4, e325-e333.	2.2	72
44	A Novel Low Affinity CD19CAR Results in Durable Disease Remissions and Prolonged CAR T Cell Persistence without Severe CRS or Neurotoxicity in Patients with Paediatric ALL. Blood, 2017, 130, 806-806.	0.6	8
45	Successful Curative Therapy With Rituximab and Allogeneic Haematopoietic Stem Cell Transplantation for MALT Lymphoma Associated With <i>STK4</i> â€Mutated CD4+ Lymphocytopenia. Pediatric Blood and Cancer, 2016, 63, 1657-1659.	0.8	13
46	<scp>UK</scp> experience of unrelated cord blood transplantation in paediatric patients. British Journal of Haematology, 2016, 172, 482-486.	1.2	6
47	An emerging opportunistic infection: fatal astrovirus (<scp>VA</scp> 1/ <scp>HMO</scp> â€C) encephalitis in a pediatric stem cell transplant recipient. Transplant Infectious Disease, 2016, 18, 960-964.	0.7	74
48	The Changing Patterns of Graft Failure in MPS1H, Hurler Syndrome: A Review of 30-Years Experience. Blood, 2016, 128, 4700-4700.	0.6	3
49	Stem cell transplantation in severe congenital neutropenia: an analysis from the European Society for Blood and Marrow Transplantation. Blood, 2015, 126, 1885-1892.	0.6	76
50	Primary pleural precursor B ell lymphoblastic lymphoma. Clinical Case Reports (discontinued), 2015, 3, 858-861.	0.2	0
51	Allogeneic Stem Cell Transplantation for Refractory Acute Myeloid Leukemia in Pediatric Patients: The UK Experience. Blood, 2015, 126, 4404-4404.	0.6	0
52	Outcomes of transplantation using various hematopoietic cell sources in children with Hurler syndrome after myeloablative conditioning. Blood, 2013, 121, 3981-3987.	0.6	183
53	Impact Of Prophylaxis With Defibrotide On The Occurrence Of Acute GvHD In Allogeneic HSCT. Blood, 2013, 122, 4591-4591.	0.6	3
54	Stem Cell Transplantation in Inherited Metabolic Disorders. Hematology American Society of Hematology Education Program, 2011, 2011, 285-291.	0.9	38

ROBERT WYNN

#	Article	IF	CITATIONS
55	Excess Heparan Sulphate Inhibits CXCL12-Mediated Hematopoietic Cell Migration and Engraftment After Bone Marrow Transplant in Mice with Mucopolysaccharidosis Type I,. Blood, 2011, 118, 4010-4010.	0.6	0
56	Risk Factor Analysis of Outcomes after Unrelated Cord Blood Transplantation in Patients with Hurler Syndrome. Biology of Blood and Marrow Transplantation, 2009, 15, 618-625.	2.0	105
57	Defibrotide (DF) for the Prevention of Hepatic Veno-Occlusive Disease (VOD) in Pediatric Stem Cell Transplantion: Results of a Prospective Phase II/III Randomized, Multicenter Study Blood, 2009, 114, 653-653.	0.6	3
58	Incidence of Veno-Occlusive Disease with IV in Busulfan Children Is Higher Than Expected: Preliminary Results of the VOD-DF Trial Blood, 2009, 114, 3344-3344.	0.6	0
59	A Comparison of Stem Cell Source in Adult and Paediatric Recipients of T-Cell Depleted Myeloablative Transplants for Standard Risk Leukaemia: No Difference in Mortality Using BM or PBSC Blood, 2009, 114, 1205-1205.	0.6	5
60	54 Vitamin K Status in Preterm Infants: A Randomised Controlled Trial to Compare Three Regimes of Prophylaxis. Pediatric Research, 2004, 56, 473-473.	1.1	1